LVS (delta) capB-vectored multiantigenic melioidosis vaccines protect against lethal respiratory Burkholderia pseudomallei challenge in highly sensitive BALB/c mice

By sjmartinez • March 22, 2024

Tullius MV, Bowen RA, Back PS, Masleša-Galić S, Nava S, Horwitz MA. LVS ΔcapB-vectored multiantigenic melioidosis vaccines protect against lethal respiratory Burkholderia pseudomalleichallenge in highly sensitive BALB/c mice. mBio. 2024 Mar 21:e0018624. doi: 10.1128/mbio.00186-24. Epub ahead of print. PMID: 38511933.

Tags: Burkholderia pseudomallei, Infectious Diseases, live attenuated vaccine, LVS ΔcapB, melioidosis, Publications, select agent, vaccine

Related Posts

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative

Wohl DA, Adam SJ, Gibbs KW, Moskowitz AL, Ortel TL, Singh U, Jilg N, Evering TH, Fischer WA 2nd, Taiwo BO, Daar ES, Lindsell CJ,[...]